Skip to main content
Go to homepage

Effectiveness of Ribociclib Following Radiation Therapy in Children with Newly-diagnosed Diffuse Pontine Gliomas

Effectiveness of Ribociclib Following Radiation in Children with Diffuse Pontine Gliomas

Description:

For complete information, please view the study on clinicaltrials.gov

This study is being done in collaboration with Cincinnati Children's Hospital.

Study Status:
Closed
Full IRB Study Title:
CLEE011XUS17T: A Phase I/II Study of Ribociclib, a CDK4/6 Inhibitor, Following Radiation Therapy in Children with Newly-diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High-grade Gliomas (HGG)
IRB Study ID:
969528-2
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org
Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research, Stem Cell Transplantation & Shannon E. Wilkes Targeted Therapy Program; Pediatric Hematologist-Oncologist;
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program